NCT05116813View on ClinicalTrials.gov

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

June 17, 2022

Study Completion Date

August 15, 2022

Conditions
Parkinson DiseaseDyskinesia, Drug-InducedDyskinesias
Interventions
DRUG

Dipraglurant

Oral 50 mg and 100 mg tablet

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

19107

University of Pennsylvania, Philadelphia

30912

Augusta University, Augusta

66160

University of Kansas Medical Center, Kansas City

08901

Rutgers, the State University of New Jersey, New Brunswick

43210-1267

The Ohio State University Wexner Medical Center, Columbus

19001-3816

Abington Neurologic Associates, Abington

Sponsors

Lead Sponsor

Addex Pharma S.A.
All Listed Sponsors
lead

Addex Pharma S.A.

INDUSTRY

NCT05116813 - Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy | Biotech Hunter | Biotech Hunter